Precigen Reports Q3 2026 Profitability and Strong Revenue Growth Driven by PAPZIMEOS
Precigen, Inc. (PGEN) reported strong third-quarter 2026 financial results, highlighted by its first instance of positive operating cash flow ($11.9 million) and significant net income of $35.8 million. The company's lead therapy, PAPZIMEOS, drove substantial commercial momentum, with quarterly net revenue reaching $72.9 million—a 37% sequential increase from the previous quarter. The growth is attributed to increased physician adoption and widespread payer coverage, which now includes approximately 100% of insured lives in the U.S. across commercial, Medicare, and Medicaid plans. With over 500 patients having started treatment and a high gross margin of 91%, management expects sustained commercial momentum as they expand their reach within the recurrent respiratory papillomatosis (RRP) market.
Tickers: $AAPL $AMZN $GOOG $META $MSFT $NVDA $PGEN $TSLA